WHO ICTRP trial
DORADO-EX – A Dose-Blinded, Long-Term, Safety Extension Study to the Phase 3…
ACTRN12606000310561 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12606000310561 |
|---|---|
| Public title | DORADO-EX – A Dose-Blinded, Long-Term, Safety Extension Study to the Phase 3 DORADO Study of Darusentan in Resistant Hypertension |
| Scientific title | DORADO-EX – A Dose-Blinded, Long-Term Safety Extension Study of Fixed Doses of Darusentan in Subjects with Resistant Systolic Hypertension Receiving Combination Therapy with Four of More Antihypertensive Drugs, Including a Diuretic (Protocol DAR-311-E) |
| Primary sponsor | Myogen, Inc. |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | United States of America |
| Conditions | Resistant Hypertension; Resistant Hypertension;Cardiovascular - Hypertension |
| Interventions | This is a dose-blinded, long-term safety and efficacy study of a new experimental drug called darusentan. Darusentan is not currently approved by the Therapeutic Goods Administration (TGA) for use in Australia, which means that a doctor… |
| Registration date | Jul 20, 2006 |
| Target size | 300 |
| Secondary IDs | Myogen Inc: Protocol DAR-311-E |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: